Alnylam’s Yvonne Greenstreet on RNAi and a ‘golden era’ in biotech
- Forfatter
- Afsnit
- 215
- Udgivet
- 29. maj 2025
- Forlag
- 0 Anmeldelser
- 0
- Afsnit
- 215 of 258
- Længde
- 30M
- Sprog
- Engelsk
- Format
- Kategori
- Økonomi & Business
Alnylam Pharmaceuticals has pioneered RNA interference therapeutics, or RNAi. This groundbreaking technology has increased the company’s success rates of bringing medicines through the clinical pipeline—leading to the approval and launch of six new medicines in just six years. Their CEO Dr. Yvonne Greenstreet spoke with Jerry Lee, head of biopharma banking in the global healthcare group, about the applications of Alnylam’s Nobel Prize-winning RNAi technology, her vision for the future of biotech, and the importance of a patient-focused and teamwork-oriented culture. Dr. Greenstreet also discussed her career journey and leadership philosophy —as one of the only women of color leading a major pharmaceutical company.
This episode was recorded on April 23, 2025. Learn more about your ad choices. Visit megaphone.fm/adchoices
Other podcasts you might like ...
- The Journal.The Wall Street Journal & Spotify Studios
- The Can Do WayTheCanDoWay
- HW News Business Tit-BitsHW News Network
- 1,5 graderAndreas Bäckäng
- Self-Compassionate ProfessorPhD
- Networth and Chill with Your Rich BFFVivian Tu
- Don't Be SourMaxx Chewning
- Mark My Words PodcastMark Homer
- EGO NetCastMartin Lindeskog
- The Pathless Path with Paul MillerdPaul Millerd
- The Journal.The Wall Street Journal & Spotify Studios
- The Can Do WayTheCanDoWay
- HW News Business Tit-BitsHW News Network
- 1,5 graderAndreas Bäckäng
- Self-Compassionate ProfessorPhD
- Networth and Chill with Your Rich BFFVivian Tu
- Don't Be SourMaxx Chewning
- Mark My Words PodcastMark Homer
- EGO NetCastMartin Lindeskog
- The Pathless Path with Paul MillerdPaul Millerd
